SCHEMBL4893783

SCHEMBL4893783

Cc1ccc2c(Cl)nnc(I)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.38
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 3/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 4/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GOT1 P17174 1/20 0.32
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
CYP1A2 P05177 3/20 0.31
CYP2A6 P11509 2/20 0.31
BCL2L1 Q07817 1/20 0.30
MCL1 Q07820 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759501 0.86 LMNA (0.44) LMNAALDH1A1KDM4EPOLBMAPT
SCHEMBL30040888 0.86 LMNA (0.44) LMNAALDH1A1KDM4EPOLBMAPT
SCHEMBL2953283 0.77 HTT (0.36) LMNAALDH1A1KDM4ESMN1; SMN2KMT2A
SCHEMBL23562822 0.76 LMNA (0.40) LMNAALDH1A1KDM4EPOLBMAPT
SCHEMBL3754272 0.70 ALDH1A1 (0.46) LMNAALDH1A1KDM4EMAPTRAB9A
SCHEMBL25544246 0.69 LMNA (0.42) LMNAALDH1A1KDM4EMAPTKMT2A
SCHEMBL3754268 0.69 FLT1 (0.39) LMNAALDH1A1KDM4EMAPTRAB9A
SCHEMBL28934710 0.67 ACHE (0.41) ALDH1A1KDM4EPOLBMAPTRAB9A
SCHEMBL4834709 0.67 CNR1 (0.45) LMNAALDH1A1KDM4EPOLBMAPT
SCHEMBL18630252 0.65 C1S (0.41) LMNAALDH1A1KDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976836-A2 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES Amgen Inc. (US) 2008-10-08 EP disclosed
WO-2007076092-A2 NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC. (US) 2007-07-05 WO disclosed